ResMed (RMD) insider Michael Farrell has filed to sell common shares under Rule 144. The notice covers 4,991 common shares to be sold through Fidelity Brokerage Services LLC on the NYSE, with an aggregate market value of 1,366,436.43 and 145,678,401 common shares outstanding.
The 4,991 shares were acquired on 02/09/2026 via an option originally granted on 11/21/2019, with the purchase price paid in cash. The filing also lists sales over the prior three months: 4,991 common shares on 12/08/2025 for gross proceeds of 1,254,795.79 and 4,991 common shares on 01/07/2026 for 1,240,065.36.
By signing the notice, the seller represents that he does not know of any undisclosed material adverse information about ResMed’s current or prospective operations.
ResMed Inc. director Peter C. Farrell, who serves as chairman emeritus, reported selling 2,000 shares of ResMed common stock on February 4, 2026 at a price of $251.31 per share. After this transaction, he beneficially owned 64,773 shares directly. The sale was executed under a pre‑arranged Rule 10b5‑1 trading plan that was adopted on August 12, 2025, indicating the trade followed an advance, systematic plan rather than a discretionary same‑day decision.
ResMed Inc.'s Global General Counsel Michael J. Rider reported a small automatic share sale under a pre-set trading plan. On 02/04/2026, he sold 50 shares of ResMed common stock at $260 per share in a transaction coded as a sale.
After this trade, he beneficially owned 9,691 shares, all reported as directly held. The filing notes that the transaction was conducted under a Rule 10b5-1 plan adopted on February 28, 2025, indicating it was pre-arranged rather than a discretionary market-timed trade.
A shareholder, Peter C Farrell, has filed a notice of intent to sell 2,000 shares of common stock through Merrill Lynch on the NYSE. The planned sale has an aggregate market value of 502540, with 44,448,959 shares of the issuer’s stock reported as outstanding and an approximate sale date of 02/04/2026.
The 2,000 shares were acquired on 11/11/2014 via a stock option transaction for cash. Over the prior three months, Peter C Farrell sold 2,000 shares on each of three dates, with gross proceeds of 504020, 502860, and 497580, indicating a pattern of periodic share sales.
A shareholder in RMD filed a Form 144 notice to sell 50 shares of common stock through Fidelity Brokerage Services LLC, with an aggregate market value of 13000.00, on or about 02/04/2026 on the NYSE. The 50 shares were acquired as restricted stock vesting on 11/11/2021 as compensation from the issuer. Over the past three months, the same account has sold 50 shares of common stock on 12/01/2025 for gross proceeds of 12208.00 and another 50 shares on 01/02/2026 for gross proceeds of 12087.50.
ResMed Inc.’s Chief Financial Officer Brett Sandercock reported a planned sale of company stock. On February 2, 2026, he sold 1,000 shares of ResMed common stock at $257.03 per share under a Rule 10b5-1 trading plan adopted on February 19, 2025.
After this transaction, Sandercock directly holds 85,495 ResMed shares. Rule 10b5-1 plans allow executives to pre-schedule trades, helping separate routine portfolio moves from day-to-day market or company news.
Brett Sandercock filed a notice of proposed sale of 1,000 shares of common stock with an aggregate market value of 257,030.00, to be sold through Fidelity Brokerage Services LLC on the NYSE around 02/02/2026.
The 1,000 shares were acquired on 11/11/2022 through restricted stock vesting from the issuer as compensation. Over the prior three months, Brett Sandercock sold 3,000 common shares on 11/03/2025 for gross proceeds of 742,620.00, 1,000 shares on 12/01/2025 for 244,160.00, and 1,000 shares on 01/02/2026 for 241,750.00.
ResMed Inc. filed a current report describing its latest quarterly results and a new dividend declaration. The company issued a press release covering operations for the quarter ended December 31, 2025, which is furnished as an exhibit and not treated as filed for liability purposes.
ResMed’s board declared a quarterly cash dividend of US $0.60 per share, with a record date of February 12, 2026, payable on March 19, 2026. The dividend will be paid in U.S. dollars to NYSE common stockholders. Holders of CHESS Depositary Instruments on the ASX will receive the equivalent in Australian dollars based on the exchange rate on the record date, reflecting the 10:1 ratio between CDIs and NYSE shares. The ex-dividend date is February 11, 2026 for both common stock and CDIs, and ResMed obtained an ASX waiver to defer conversions between its common stock and CDI registers from February 11–12, 2026.
ResMed Inc. director Peter C. Farrell reported a sale of company stock. On January 7, 2026, he sold 2,000 shares of ResMed common stock at a price of $248.83 per share. After this transaction, he beneficially owned 66,773 shares directly. The filing notes that the trade was conducted under a Rule 10b5-1 trading plan that was adopted on August 12, 2025, which is a pre-arranged plan that allows insiders to systematically sell shares over time.
ResMed Inc.'s Chairman and CEO Michael J. Farrell reported an options exercise and stock sale. On January 7, 2026, he exercised 4,991 ResMed common stock options at an exercise price of $146.34 per share, receiving the same number of ResMed common shares. On the same day, he sold 4,991 ResMed common shares at a weighted average price of $248.4603 per share, in multiple trades between $246.801 and $249.969.
The transactions were conducted under a Rule 10b5-1 trading plan adopted on October 31, 2024. Following these transactions, Farrell directly beneficially owned 466,223 ResMed common shares, held in his own name, and indirectly beneficially owned 2,090 shares through the Lisette and Michael Farrell Family Trust. He also held 49,912 ResMed common stock options after the reported exercise; these options first became exercisable on November 11, 2020 and vest one-third per year.